Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 70518-4110

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 70518-4110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Clopidogrel 75mg 70518 4110 01)

The label for Clopidogrel bisulfate 75 mg film-coated tablets shows a quantity of 30 tablets. It includes the NDC number 70518-4110-01, indicates the product is prescription-only, and lists RemedyRepack Inc. as the labeler. The label features storage instructions, manufacturer details for ScieGen Pharmaceuticals, and a barcode with a QR code.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Clopidogrel 75 mg film-coated tablets, quantity of 90 tablets. The label includes the NDC 70518-4110-00, identifies the manufacturer as ScieGen Pharmaceuticals, Inc., Hauppauge, NY, and the repackager as RemedyRepack Inc., Indiana, PA. Storage instructions and a barcode are also visible.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A figure illustrating the effect of proton pump inhibitors (PPIs) dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg on exposure to clopidogrel active metabolite following multiple doses of clopidogrel 75 mg. The graph shows mean and 90% confidence intervals of active metabolite AUC change relative to clopidogrel administered alone, with values ranging approximately from 0.4 to 1.4 on the x-axis.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up comparing placebo (+ aspirin) and clopidogrel (+ aspirin) treatments. The graph indicates lower event rates with clopidogrel plus aspirin than with placebo plus aspirin, with a p-value of 0.00009. A note states that other standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

Two forest plots summarize hazard ratios with 95% confidence intervals comparing Clopidogrel bisulfate 75 mg tablet versus placebo across various patient subgroups. The subgroups include age, gender, race, cardiac enzyme elevation, diabetes, previous MI and stroke, heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker, and ACE inhibitor use, showing the relative treatment effect on outcomes by each subgroup.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing percent dead before first discharge over days since randomization up to 28 days. It compares death rates for placebo (8.1%) and Clopidogrel (7.5%) groups, with a noted 7% proportional risk reduction (p=0.03). A footnote states all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A survival curve chart comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days between placebo and clopidogrel groups. The x-axis shows days since randomization (0 to 28), and the y-axis shows the percentage of events (0% to 11%). Placebo patients show a higher event percentage (10.1%) than clopidogrel patients (9.2%), with a noted 9% proportional risk reduction (p=0.002) for clopidogrel.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot chart showing the effects of adding Clopidogrel to aspirin on the combined primary endpoint across various subgroups in the COMMIT study. It compares odds ratios with 99% confidence intervals for Clopidogrel versus placebo by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, with a vertical line indicating no effect.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rates (%) over 36 months of follow-up. It compares two lines labeled 'Aspirin' and 'Clopidogrel', with clopidogrel consistently having a lower cumulative event rate. A p-value of 0.045 is indicated on the graph.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A figure titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study' displaying a forest plot. It compares hazard ratios between Clopidogrel and Aspirin across subgroups: Stroke, MI, PAD, and Overall. The x-axis shows hazard ratios from 0.6 to 1.3, with markers indicating favor towards Clopidogrel or Aspirin.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of Clopidogrel bisulfate, showing the molecular arrangement with a thiophene ring, piperidine ring, ester group, chloro-substituted benzene ring, and associated sulfuric acid (H2SO4) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.